Novel therapeutic targets in Waldenstrom macroglobulinemia

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Understanding of molecular mechanisms that drive Waldenstrom macroglobulinemia (WM) cell survival are rapidly evolving. This review briefly highlights emerging “WM-relevant” targets; for which therapeutic strategies are currently being investigated in preclinical and clinical studies. With the discovery of MYD88L265P signaling and remarkable activity of ibrutinib in WM, other targets within the B-cell receptor pathway are now being focused on for therapeutic intervention. Additional targets which play a role in WM cell survival include TLR7, 8 and 9, proteasome-associated deubiquitinating enzymes (USP14 and UCHL5), XPO1/CRM1 and AURKA. New drugs for established targets are also discussed. Lastly, we spotlight 3 highly innovative WM-specific therapies: MYD88 peptide inhibitors, MYD88L265P-directed immune activation and CD19-directed chimeric antigen receptor T-cell therapy, which are in various stages of development. Indeed, treatment of WM is poised to undergo a paradigm shift in the coming years towards highly disease-driven and more personalized therapeutic modalities with curative intent.

Original languageEnglish (US)
Pages (from-to)216-228
Number of pages13
JournalBest Practice and Research: Clinical Haematology
Volume29
Issue number2
DOIs
StatePublished - Jun 1 2016

Fingerprint

Waldenstrom Macroglobulinemia
Cells
Aurora Kinase A
Proteasome Endopeptidase Complex
T-Cell Antigen Receptor
Cell Survival
Therapeutics
Chemical activation
Peptides
Antigen Receptors
Enzymes
Cell- and Tissue-Based Therapy
Pharmaceutical Preparations
B-Lymphocytes

Keywords

  • Deubiquitinating enzymes
  • Ibrutinib
  • MYD88
  • Proteasome
  • Waldenstrom macroglobulinemia

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Clinical Biochemistry

Cite this

Novel therapeutic targets in Waldenstrom macroglobulinemia. / Paulus, Aneel; Ailawadhi, Sikander; Chanan Khan, Asher A.

In: Best Practice and Research: Clinical Haematology, Vol. 29, No. 2, 01.06.2016, p. 216-228.

Research output: Contribution to journalReview article

@article{54a74412f6864bb7a8e19d919a6677bd,
title = "Novel therapeutic targets in Waldenstrom macroglobulinemia",
abstract = "Understanding of molecular mechanisms that drive Waldenstrom macroglobulinemia (WM) cell survival are rapidly evolving. This review briefly highlights emerging “WM-relevant” targets; for which therapeutic strategies are currently being investigated in preclinical and clinical studies. With the discovery of MYD88L265P signaling and remarkable activity of ibrutinib in WM, other targets within the B-cell receptor pathway are now being focused on for therapeutic intervention. Additional targets which play a role in WM cell survival include TLR7, 8 and 9, proteasome-associated deubiquitinating enzymes (USP14 and UCHL5), XPO1/CRM1 and AURKA. New drugs for established targets are also discussed. Lastly, we spotlight 3 highly innovative WM-specific therapies: MYD88 peptide inhibitors, MYD88L265P-directed immune activation and CD19-directed chimeric antigen receptor T-cell therapy, which are in various stages of development. Indeed, treatment of WM is poised to undergo a paradigm shift in the coming years towards highly disease-driven and more personalized therapeutic modalities with curative intent.",
keywords = "Deubiquitinating enzymes, Ibrutinib, MYD88, Proteasome, Waldenstrom macroglobulinemia",
author = "Aneel Paulus and Sikander Ailawadhi and {Chanan Khan}, {Asher A}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.beha.2016.08.020",
language = "English (US)",
volume = "29",
pages = "216--228",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Novel therapeutic targets in Waldenstrom macroglobulinemia

AU - Paulus, Aneel

AU - Ailawadhi, Sikander

AU - Chanan Khan, Asher A

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Understanding of molecular mechanisms that drive Waldenstrom macroglobulinemia (WM) cell survival are rapidly evolving. This review briefly highlights emerging “WM-relevant” targets; for which therapeutic strategies are currently being investigated in preclinical and clinical studies. With the discovery of MYD88L265P signaling and remarkable activity of ibrutinib in WM, other targets within the B-cell receptor pathway are now being focused on for therapeutic intervention. Additional targets which play a role in WM cell survival include TLR7, 8 and 9, proteasome-associated deubiquitinating enzymes (USP14 and UCHL5), XPO1/CRM1 and AURKA. New drugs for established targets are also discussed. Lastly, we spotlight 3 highly innovative WM-specific therapies: MYD88 peptide inhibitors, MYD88L265P-directed immune activation and CD19-directed chimeric antigen receptor T-cell therapy, which are in various stages of development. Indeed, treatment of WM is poised to undergo a paradigm shift in the coming years towards highly disease-driven and more personalized therapeutic modalities with curative intent.

AB - Understanding of molecular mechanisms that drive Waldenstrom macroglobulinemia (WM) cell survival are rapidly evolving. This review briefly highlights emerging “WM-relevant” targets; for which therapeutic strategies are currently being investigated in preclinical and clinical studies. With the discovery of MYD88L265P signaling and remarkable activity of ibrutinib in WM, other targets within the B-cell receptor pathway are now being focused on for therapeutic intervention. Additional targets which play a role in WM cell survival include TLR7, 8 and 9, proteasome-associated deubiquitinating enzymes (USP14 and UCHL5), XPO1/CRM1 and AURKA. New drugs for established targets are also discussed. Lastly, we spotlight 3 highly innovative WM-specific therapies: MYD88 peptide inhibitors, MYD88L265P-directed immune activation and CD19-directed chimeric antigen receptor T-cell therapy, which are in various stages of development. Indeed, treatment of WM is poised to undergo a paradigm shift in the coming years towards highly disease-driven and more personalized therapeutic modalities with curative intent.

KW - Deubiquitinating enzymes

KW - Ibrutinib

KW - MYD88

KW - Proteasome

KW - Waldenstrom macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84994514643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994514643&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2016.08.020

DO - 10.1016/j.beha.2016.08.020

M3 - Review article

C2 - 27825468

AN - SCOPUS:84994514643

VL - 29

SP - 216

EP - 228

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 2

ER -